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Abstract  
The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor and a member of the epidermal 
growth factor receptors (EGFR/ErbB) family. Over-expression of this oncogene is known to contribute to 
pathogenesis and aggressive progression in breast cancer. On the other hand, angiogenesis is a physiological 
process of forming new blood vessels from pre-existing ones; however it is essential for tumor growth and 
transitional from benign stage to malignant form and also fundamental process for metastasis of tumors. In this 
study the main aim was to investigate whether angiogenesis is the cause for increased aggressive behavior of 
HER2 overexpression subtype in breast cancer. A variety of approaches were employed to investigate the main 
aim: quantification of angiogenesis using a mouse cancer cells implanted model; Drabkin’s assay for hemoglobin 
measurement; morphology assessment of cell lines; Bio-Plex analysis of angiogenesis factors angiopoietin-2, 
follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-BB, PECAM-1 and VEGF; and reverse transcriptase-PCR on 
VEGFA and HIF-1 alpha genes expression. The data from this study showed that the AU-565 cell line which 
over-expresses HER2 receptors showed a significant decrease in both tumor weight and hemoglobin measurement 
when the cells were treated with anti-HER2 implanted in nude mice. Also, the data showed an increased 
expression of angiogenic factors and genes (mainly VEGF, VEGFA, Angiopoietin, and IL-8) in AU-565 as 
compared to MCF-7 cells, which have low expression of HER2 receptors. This suggests that breast cancer with 
HER2/neuoncogenes is associated with more angiogenic activities that result in an increased aggressive behavior 
of this form of cancer.  
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Introduction 
According to the National Cancer Institute, 
the number of estimated new cases of breast 
cancer in the United States in 2011 was 
230,480 for females and 2,140 for males. In 
the same year, the mortality rates attributed to 
breast cancer in the United States were 
predicated to be 39,520 for females and 450 
for males[1].Despite ongoing clinical research 
and the intensive involvement of the medical 
community, the high prevalence of this 
disease has declined only slightly in recent 
years. 
Treatment and prognosis are dependent on 
the accurate classification of receptor status 
and staging of the breast cancer. The common 
classification of breast cancer includes: 
histopathological, grading, staging, receptors 
status (ex; ER, PR, HER2), and DNA 
microarray for gene profiling. The newer 
approach has integrated receptors status and 
gene profile of the tumor to establish 
molecular subtypes of breast cancer which 
are: luminal A, luminal B, triple negative (or 
basal-like), and human epidermal growth 
factor receptor 2 (HER2) over-expression. In 
clinical practice, particular attention has 
focused on A, B, and triple negative luminal 
subtypes versus HER2 positive 
over-expression subtype. The HER2 receptors 
over-expression is present in 25 to 30 percent 
of breast cancer[2]. In a study involving 222 
invasive breast carcinoma cases, it was 
reported based on survival rates that theHER2 
over-expressing subtype had the worst 
prognosis due to a high rate of invasion and 
metastasis [3]. 
There are many drugs of monoclonal 
antibodies found to minimize immunogenicity 
of cancer cells over-expressed with HER2, the 
most common is Trastuzumab (commercially 
known as Herceptin). Trastuzumab however, 
was found to be associated with many 
negative side effects when used alone [4]. 
Angiogenesis on the other hand plays an 
important role in tumor invasion and 
metastasis, it occurs because there is either an 
increase in the pro-angiogenic molecules or 
decrease in the anti- angiogenic 
stimuli[5].Studies have shown that there is a 
proportional increase in the growth of 
leukemia and other hematological 
malignancies related to their degree of 
angiogenesis[6]. Also, other experimental 
data suggested that the intensity of 
angiogenesis in a human tumor could predict 
the probability of metastasis as an example in 
cutaneous melanoma[7]. 
Many angiogenesis genes have been 
identified in experiments of stimulation of 
angiogenesis using a variety of different 
mechanisms. Most commonly, markedly 
increased expression of VEGFA and HIF-1 
Alpha have been studied in breast cancer 
using the reverse transcriptase-PCR 
method[8]. Also, it has been found that 
over-expression of HER2 in human tumor 
cells are closely associated with angiogenesis 
as when the VEGF pathway was inhibited, 
tumor cells growth were suppressed and 
further experiment has shown that anti-HER2 
inhibits tumor cell growth  and VEGF 
expression[9]. 
In this study the main aim was to study 
whether angiogenesis is the cause for 
increased aggressive behavior of HER2 
overexpression subtype in breast cancer. Such 
a finding could possibly lead to a better 
understanding of breast cancer 
pathophysiology and result in an improved 
method of target therapy in the more 
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aggressive tumors.Also the study could 
produce new diagnostic and prognostic 
markers for the clinical staging of breast 
cancer based on the expression of 
angiogenesis in the various subtypes. 
Materials and Methods 
Materials  
Material used were: human breast cancer cell 
lines MCF-7, MDA-MB-231, and AU-565 
(American Type Culture Collection ATCC, 
VA, USA); Dulbecco's Modified Eagle 
Medium DMEM (Invitrogen, Life Sciences, 
NJ, USA); Roswell Park Memorial 
Institute-1640 RPMI-1640 (ATCC); Matrigel 
(BD Biosciences); Anti-HER2 conjugated 
with fluorescence (BD Biosciences, Becton 
Dickson); Anti-HER2 inhibitors (Abcam, MA, 
USA); VILO Master Mix (Invitrogen); 
Angiogenesis kit (Bio-Rad, CA); Bio-Plex 
200 System (Bio-Rad); FACSCaliburFlow 
cytometry (BD Biosciences); Confocal 
microscopy TCS SP8 (Leica, NJ, USA); Real 
time-PCR (Applied Biosystems, Eppendorf, 
NY, USA). 
Cell Culture 
The MCF-7, MDA-MB-231, and AU-565 cell 
lines were propagated in the cell culture at 
37°C, 5% CO2. The media used was DMEM 
with 10% FBS for MCF-7 and MDA-MB-231 
and RPMI-1640 with 10% FBS for AU-565.  
Mouse Model 
The animal experiment was conducted at the 
VA Medical Center (Albany, N.Y) animal 
facility. All experiments were performed in 
compliance with Public Health Service Policy 
on HumaneCare and Use of Laboratory 
Animals and approved by the VA Medical 
Center IACUC. At the end of the study the 
mice were sacrificed humanely. Female nude 
homozygous mice aged 5-6 weeks with body 
weights of 20 g were obtained from Taconic 
Farms (Hudson, NY). 
Standardization of the cell lines 
The first step was to sort out the cell lines that 
are over-expressed with HER2 receptors using 
flow cytometry technique. We used the 
SKO3-LU ovarian cell line, known to be 
over-expressed with the HER2 receptors as a 
positive control [10]. Cells were taken from 
cell culture, washed twice with phosphate 
buffer saline, and then the samples were 
divided into two sets. Each set of samples 
contained 1x106 cells.The first set of samples 
was unstained with anti-HER2, while the 
second set was stained with 50 ul of 
fluorescence-conjugated monoclonal antibody. 
Both sets were incubated in the dark for 30 
minutes. Then the samples were analyzed and 
signals were acquired on a FACSCalibur flow 
cytometry (BD Biosciences). CellQuest 
software (version 3.2) was used to acquire 
data. The HER2-positive cells were visualized 
in a histogram showing fluorescence 
(APC-positive) events. An acquisition 
threshold (Laser excitation at 488 nm and 635 
nm) was set so that any unwanted events like 
HER2-negative cells, dead cells and debris are 
not recorded. 
Morphology Study 
The experimental goal of a morphology study 
was to classify the cell lines according to the 
Kenny et al. study[11]. MCF-7, 
MDA-MB-231, and AU-565 cell lines were 
viewed after 48 hours of the first cell 
sub-culture using a two dimensional culture 
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and a stereomicroscope. In addition, the cell 
lines were stained with cell tracker CMFDA 
(5-choromethylfluorescein diacetate) in order 
for the cells to be visualized under the 
fluorescent microscope. Morphology 
descriptions of the cell lines were classified 
whether round, mass, grape-like, or stellate 
shapes.  
Quantification of Angiogenesis in 
Vivo 
The aim of this experiment was to quantify 
angiogenesis in a female nude mouse model. 
One million MCF-7, MDA-MB-231, and 
AU-565 cells were suspended in 50 ul of 
media and mixed with 50 ul of matrigel. The 
total mixture (100 ul) was implanted in the 
mammary glands (two inoculations) and 
subcutaneously (two inoculations) in each 
mouse (total two mice for each cell lines). The 
control for the HER2 receptors was run on the 
AU-565 cell line (over-expressed with the 
HER2 receptors). Each control inoculation 
consisted of one million of AU-565 cells 
suspended in 30 ul of media, 20 ul of 0.2 
mg/ml anti-HER2 inhibitors, and 50 ul of 
matrigel, adding to the final concentration of 
4 ug of anti-HER2 per one million of cells. 
After two weeks, the mice were sacrificed and 
the tumors were harvested, and tumor weights 
were recorded. Homogenization of the tumors 
and then a centrifugation step followed. 
Drabkin’s reagent was added and then the 
samples were incubated for 15 minutes before 
the hemoglobin concentration was measured 
using a colorometric ELISA reader. The 
absorbance was measured at 540 nm and the 
hemoglobin concentration was expressed as 
mg/ml based on comparison with a standard 
curve.  
Multiplex Analysis 
The aim of this experiment was todetect the 
expression level of the following angiogenesis 
factors using multiplex analysis technique in 
MCF-7, MDA-MB-231, and AU-565 cell 
lines: angiopoietin-2, follistatin, G-CSF, HGF, 
IL-8, leptin, PDGF-BB, and VEGF. Media 
samples were taken from each cell line after 
48 hours from the sub-culturing, and run on a 
Bio-Plex 200 System using an angiogenesis 
kit from Bio-Rad. A 96-well plate was used 
after being pre-wetted with assay buffer.  
Then, 50 ul of coupled magnetic beads were 
added in each well, followed by a washing 
step with PBS performed twice. Lyophilized 
controls and standards were reconstituted and 
8-point serial dilutions of standard were made. 
Then 50 ul of two blanks (both media RPMI 
and DMEM), controls, standards, and samples 
were taken and added in each well accordingly. 
Each sample was run in triplicate.  The 
samples were incubated and vortexed at room 
temperature for 30 minutes. Then the samples 
were washed twice with PBS.Next, 50ul of 
pre-diluted detection antibodies were added in 
each well, followed by 30 minutes of 
incubation at room temperature and washing 
twice with PBS. Then, streptavidin-PE was 
added (50 ul) in each well, followed by 10 
minutes incubation under agitation. The 
samples were washed twice andthe mixture in 
each well was suspended in 125 ul of assay 
buffer. Data acquisition was performed using 
Bio-Plex Manager Software version 5.0.   
RT-PCR 
The experimental aim was to determine the 
expression level of HIF-1 Alpha and VEGFA 
genes using reverse transcriptase-PCR 
(RT-PCR). Primer designation for the genes 
was taken from the National Center for 
Biotechnology Information NCBI. (Table.1). 
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Table 1.Nucleotides Length, Primers Sequences, and Annealing Temperature for Genes. 
 
Gene 
Entrez 
Gene 
ID 
Length 
(bp) 
Primers Sequence 
Annealing 
Temp (oC) 
HIF-1 
Alpha 
134 
3091 Forward 
Primer 
‘5-CGTTCCTTCGATCAGTTGTC-3’ 
60.00 
Reverse 
Primer 
‘5-TCAGTGGTGGCAGTGGTAGT-3’ 
VEGFA 76 
7422 Forward 
Primer 
‘5-AGGAGGAGGGCAGAATCATCA-3’ 
60.00 
Reverse 
Primer 
‘5-CTCGATTGGATGGCAGTAGCT-3’ 
 
RNAs extraction was performed on MCF-7, 
MDA-MB-231, and AU-565 cell lines taken 
from cell culture. Cells were treated with 
TRIzol to extract the RNAs, after which the 
RNA was isolated using 100% isopropanol 
followed by a washing step with 75% ethanol 
(twice). Next, the RNA was suspended in 
RNAase-free water and a reverse transcription 
reaction was performed. Each reaction tube 
contained: 4 ul of VILO Master Mix, 8 ul of 
RNAs, and then DEPC-treated water was 
added to final volume of 20 ul. The mixture 
was incubated through a series of thromcycler 
reactions (25oC for 10 mins, 42oC for 60 mins, 
and 85oC for 10 mins). The resultant cDNA 
was used for a Real Time-PCR reaction. Each 
reaction tube contained 1 ul of each forward 
and reverse primers, 2 ul of cDNAs, 10 ul of 
SYBR GeneAmp® Fast PCR Master Mix, and 
then RNA-free water was added for a total 
volume of 20 ul. After that, the mixtures were 
processed by real time-PCR using the 9800 
Fast Thermal Cycling Profile. The 
comparative C
T 
Method (ΔΔCT) was used to 
quantify the gene expression. GAPDH was 
used as the endogenous control. For a valid 
ΔΔC
T 
calculation, the efficiency of the target 
amplification and the efficiency of the 
reference amplification were run. In a 
validation experiment that passed, the 
absolute value of the slope of ΔC
T 
vs. log 
input was < 0.1. 
Results 
Standardization of the cell lines 
SKOV3-LUC, positive control, showed 61.5% 
positivity of HER2 expression. MCF-7 cell 
line has low expression of the HER2 receptors 
with 16.6% positivity. On the contrary, 
AU-565 cells showed an over-expression of 
HER2, a 91.1% positivity. Hence, AU-565 is 
considered to be over-expressed with the 
HER2 receptors. The flow cytometry results 
were consistent with other studies using 
immuno-histochemistry because they showed 
that AU-565 cells over-express the HER2 
receptors, while MCF-7 cells are negative for 
expression[12]. 
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Figure 1 (A) SKOV3-LUC as a positive control with anti-HER2 staining. Note: gate P3 (positive gate) 
showed positivity 61.5%. (B) AU-565 cells with anti-HER2 staining showed 95.1% toward gate P3 (high 
expression), while it showed 4.9% negativity. (C) MCF7 cells with anti-HER2 staining showed 16.6% 
toward gate P3 (minimal expression), while it showed 84.4% toward gate P5 (negative gate).  
 
Table 2 Tumor weights of the breast cancer cell lines after harvest from mice after two weeks.  
 
 
 
 
 
 
 
 
 
 
 
Angiogenesis Quantification in Vivo 
The results of Drabkin’s assay for hemoglobin 
measurement after the tumors were harvested 
from mice (two weeks incubation) showed 
significant variance between AU-565 cell line, 
which expresses HER2, and the AU-565 cell 
lines treated with anti-HER2 (Figure 2). The 
average tumor weight resulting from the 
AU-565 cell line after treatment with 
anti-HER2 showed a notable decrease (Table 
2) compared with AU-565. The tumors 
resulting from the AU-565 cell line had more 
tumor growth and hemoglobin concentration 
than MCF-7 by 24.3% and 24.7%, 
respectively. (Table 2 and Figure 3). 
 
 
 
 
Figure 2 Hemoglobin concentration of tumors 
of AU-565 cell line and AU-565 treated with 
HER2 inhibitors after implanted in mice. 
AU-565 with HER2 inhibitors showed a 37.3% 
decrease compared to the AU-565 cell line. 
 
Tumor's Weight in mg 
 AU-565 AU-565 w/ anti-HER2 MCF-7 
 35.3 11 14.5 
 30.9 11.9 20.9 
 31 12.1 26.9 
     19.7 
     16.7 
     8.5  
Average 32.4 11.7 19.7 
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Figure 3 Hemoglobin concentration of tumors 
AU-565 and MCF-7 cell lines were implanted in 
nude mice. AU-565 cells showed a more 
hemoglobin’s concentration than MCF-7 cells by 
24.7%.  
Morphology Study 
The MCF-7 cell line showed the Mass class 
morphology as the cells formed colonies with 
round colony outlines. They are distinguished 
from the round morphological grouping by 
their disorganized nuclei and filled colony 
centers. While, the AU-565 cell line exhibited 
a Grape-like class morphology, since these 
cells formed colonies with poor cell-cell 
contacts and were distinguished by their 
grape-like appearance, (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure4 Morphologies of MCF-7 and AU-565 cell lines pictured after 48 hours of first cell sub-culture 
using two dimensional cell culture and stereomicroscopy. Cells were stained with cell tracker CMFDA 
(5-choromethylfluorescein diacetate). 
 
Bio-Plex Analysis 
The results of the Bio-Plex angiogenesis assay 
showed that AU-565 cells which over-express 
HER2 had the predominance expression for 
most of the angiogenic factors studied. 
However, it showed only a significant 
expression of Angiopoietin, IL-8, and VEGF. 
While, MCF-7 cells showed less expression 
for most of the angiogenic factors studied 
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(Figures 5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 48 hours measurement of angiogenesis factors.The AU-565 cell line exhibited a significant 
higher expression of Angiopoietin, IL-8, and VEGF than MCF-7 cell line by 17.1%, 67%, and 34%. * 
P-Value less than 0.05(AU-565 more than MCF-7); **P-Value less than 0.02 (AU-565 more than 
MCF-7); ***P-Value less than 0.01 (AU-565 more than MCF-7); ■P-Value less than 0.05 (MCF-7 more 
than AU-565; ■■P-Value less than 0.01 (MCF-7 more than AU-565) 
 
RT-PCR 
Overall, the results of reverse 
transcriptase-PCR indicated that the MCF-7 
and AU-565 cell lines exhibited more 
expression of VEGFA than HIF-1 alpha genes. 
AU-565 cell line, which over-expresses the 
HER2 receptors, showed  higher expression 
of both VEGFA and HIF-1 Alpha, than MCF-7 
cell line (Figures 6 and 7). The validation 
experiment for VEGFA and HIF-1 Alpha 
genes showed the slop values were 0.063 and 
0.087, respectively (less than 0.1), which 
indicates our  ΔΔCT calculation for VEGFA 
and HIF-1 Alpha are valid.  
 
 
 
 
 
 
Figure 6 RT-PCR expression of VEGFA gene. 
AU-565 cell line showed comparable expression 
of VEGFA to MCF-7 cell line. 
 
 
 
 
 
 
 
 
Figure 7 RT-PCR expression of HIF-1 Alpha. The 
AU-565 cell line showed comparable expression 
of HIF-1 Alpha to MCF-7. 
MDA-MB-231 Cell line 
For further data generating we looked at 
MDA-MB-231 cell line which exhibits an 
aggressive proliferation rate. The flow 
cytometry results showed that MDA-MB-231 
is low expresses HER2 receptors around 1.1% 
in comparison to 61.5% SKOV3-LUC 
(control) and 84.4% AU-565 (figure 8). The 
vivo study showed that the tumors resulting 
from the MDA-MB-231 cells after implanted 
in mice had higher in both tumor weight and 
hemoglobin concentration by 13.8% and 
25.2%, respectively than AU-565 cell line 
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(Table 3 and Figure 9). The morphology of 
MDA-MB-231 cell line showed Stellate 
(elongated) projections that often bridge 
multiple cell colonies (Figure 10). In addition, 
Bio-Plex analysis showed MDA-MB-231 cells 
had a higher expression of follistatin, G-CSF, 
HGF, leptin, and PDGF-BB angiogenesis 
factors than AU-565 cells (Figure 11). In 
contrast, the RT-PCR experiment showed that 
MDA-MB-231 cells had less expression of 
VEGFA and HIF-1 Alpha genes compared 
with AU-565 cell lines (Figure 12 & 13). 
 
 
 
 
 
 
 
 
Figure 8 (A) SKOV3-LUC as a positive control with anti-HER2 staining. Note: gate P3 (positive gate) 
showed positivity 61.5%. (B) AU-565 cells with anti-HER2 staining showed 95.1% toward gate P3 (high 
expression) (C) MDA-MB-231 cells with anti-HER2 staining showed 1.1% toward gate P3 (positive), 
while it showed 98.8% negativity.  
 
Table 3 Tumor weights of the breast cancer AU-565 and MDA-MB-231 cell lines after harvest from mice 
after two weeks. Note, highlighted weights indicate the tumors were implanted in the nude mice 
mammary glands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Hemoglobin concentrations of tumors after AU-565 and MDA-MB-231 cell lines were 
implanted in nude mice. MDA-MB-231 showed more hemoglobin concentration by 13.8% than 
AU-565 cell line. 
Tumor's Weight  (mg) 
 
AU-565 MDA-MB-231 
35.3 45.6 
30.9 38.9 
31 43.1 
 44.5 
 49.6 
 35 
Average 32.4 42.8 
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Figure 10 Morphologies of MDA-MB-231 and AU-565 cell lines pictured after 48 hours of first cell 
sub-culture using two dimensional cell culture and stereomicroscopy. Cells were stained with cell tracker 
CMFDA (5-choromethylfluorescein diacetate). 
 
 
Figure 11 48 hours measurement of angiogenesis factors.MDA-MB-231 cells showed a higher expression 
of follistatin, G-CSF, HGF, leptin, and PDGF-BB than AU-565 by 84.0%, 97.0%, 31.4%, 23.5%, and 
18.8%, respectively. While, AU-565 cells showed more expression of Angiopoietin, IL-8, and VEGF 
compared to MDA-MB-231 cells by 28.5%, 3.8% & 4.6%.  *P-Value is less than 0.05 (MDA-MB-231 
more than AU-565); ■P-Value is less than 0.05 (AU-565 more than MDA-MB-231) 
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Figure 12 RT-PCR expression of VEGFA gene. 
The AU-565 cell line had a higher expression of 
VEGFA approximately 82.5% higher than 
MDA-MB-231cell line. 
 
 
 
 
 
 
 
 
Figure 13 RT-PCR expression of HIF-1 Alpha. 
The AU-565 cell line showed more expression of 
HIF-1 Alpha than MDA-MB-23 cell line around 
58.5%. 
Discussion 
Angiogenesis Quantification in Vivo 
In order to have a complete appraisal of 
angiogenesis in breast cancer cell lines, we 
investigated angiogenesis in vivo and vitro. In 
vivo study nude mice were used to quantify 
angiogenesis by implanting the tumor cells 
subcutaneously and in mammary glands, after 
two weeks, tumor weights were recorded in 
refection of tumors aggressiveness and the 
amount of hemoglobin is a proportional to 
vascularity formation of the tumors. AU-565 
cell line which expresses HER2 showed 
significant increase of tumor weight and 
hemoglobin measurement when compared 
with AU-565 cells treated with anti-HER2 
inhibitors and MCF-7 cell line which low 
expresses HER2. This finding is consistent 
with other cell lines which also over-express 
the HER2 receptors (Sk-Br-3 and BT-474 cell 
lines), the proliferation rate was inhibited 
when the cells incubated with 
anti-HER2/neu(c-erbB-2 mouse IgG1 
MAb ,Triton) at 0.025, 0.25, and 2.5 ug/ml 
concentrations for 24, 48, and 72 hours[13]. 
This finding indicates that HER2 oncogenes 
contribute in proliferation rate of tumor cells 
by stimulating of angiogenesis formation.  
Cell Lines Morphology Study  
Kenny’s study reported that the breast cancer 
cell lines in general exhibited a distinct 
morphology class and some of these 
morphologies were associated with tumor cell 
invasiveness and originating from 
metastases[11].In our study, the MCF-7 cell 
line exhibited a Mass class morphology which 
is frequently associated with a lesser 
capability to invade and metastasize. MCF-7 
cells exhibiting this morphology are 
consistent with the low expression of the 
HER2 receptors and less proliferating rate by 
these cells.  
While, AU-565 cell line showed a Grape-like 
class morphology, which forms colonies with 
poor cell-cell contacts and are distinguished 
by their grape-like appearance. Kenny et al. 
noted in their study that cell lines that 
exhibited this type of morphology were 
isolated from tumor metastases[11].The 
AU-565 cell line was confirmed in our lab to 
over-expresses the HER receptors. In general, 
these cells formed less closely associated 
colonies with reduced cell-cell adhesion as 
compared to cell lines of the other 
morphologies. This may reflect, in part, the 
acquired ability of these cells to break away 
from their neighbors in the primary tumor 
over the course of their evolution as they 
acquired the ability to metastasize.  
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Bio-Plex Analysis  
In this study we used the Bio-Plex Pro Human 
Angiogenesis Multiplex Assay to compare the 
expression of angiopoietin-2, follistatin, 
G-CSF, HGF, IL-8, leptin, PDGF-BB, and 
VEGF in breast cancer cells lines that 
over-express HER2 (AU-565) and one that 
does not (MCF-7). Our results showed that the 
expression level of these markers in the 
MCF-7 and AU-565 cell lines are markedly 
elevated as compared with normal 
physiological donors’ plasma[14]. AU-565 
cells showed a significant expression of 
Angiopoietin-2, IL-8, and VEGF. Past studies 
have indicated that the levels of IL-8 and 
VEGF are significantly increased in colon 
cancer patients[15]. Similarly, Angiopoietin-2 
had the highest expression by real time-PCR 
in Sk-Br-3 breast cancer cells which is a 
similar cell line to AU-565 cells[16].  
 RT-PCR  
VEGF-A and HIF-1 alpha genes are known 
for their significant stimulation of 
angiogenesis. VEGF-A induces endothelial 
cell proliferation, promotes cell migration, 
inhibits apoptosis and induces permeability of 
blood vessels[17]. HIF-1 alpha is a critical 
regulatory protein of cellular response to 
hypoxia and is closely related to the triggering 
of the angiogenic process[18]. Expression 
analysis of VEGF-A and HIF-1 alpha genes 
using quantitative reverse transcriptase-PCR 
suggested a significant variance between cell 
lines that over-expresses HER2 (AU-565) and 
the one that minimally expresses HER2 
(MCF-7).  The results of this study showed 
that AU-565 cells have a significant over 
expression of VEGF-A as compared with 
MCF-7 cell line. This finding was consistent 
with a study done on tGLI1 and VEGF-A as 
tGLI1 expression is proportional to 
expression of VEGF-A; they found that in 
BT-474 cell line (also over-expresses with 
HER2) has high expression of tGLI1 than 
MCF-7 cells which promotes secretion of 
VEGFA [19]. 
The HIF-1 Alpha gene was relatively less 
expressed in the MCF-7 and AU-565 cell lines. 
In other studies, the expression of HIF-1α 
protein and HIF-1 DNA-binding activity was 
found to be significantly higher in stable 
transfectants of mouse NIH 3T3 cells 
expressing HER2 than MCF-7 under 
non-hypoxic conditions [20]. Our results 
correlated with previously published studies 
where AU-565 cells showed more expression 
of HIF-1α than MCF-7 cells. However, this 
assay needs a large scale of normal cell lines 
to determine the normal expression of 
VEGF-A & HIF-1α. 
Is HER2 only factor contributes in 
aggressive behavior of angiogenesis 
in tumors? 
In this study we looked at MDA-MB-231 
which shows aggressive proliferating rate. 
MDA-MB-231 cell line is a triple negative 
(ER, PR, HER2) and also expresses the both 
epidermal growth factor (EGF), and 
transforming growth factor alpha (TGF 
alpha)[21]. Also, these cells are positive for 
the TP53 mutation[22]and this would explain 
the reason this cell line has more proliferation 
rate than AU-565 cell line which expresses 
HER2 receptors. The results of angiogenesis 
quantification in vivo, showed that 
MDA-MB-231 had slightly higher 
(statistically non-significant) in both tumor 
weight and hemoglobin’s measurement. Also, 
the morphology of MDA-MB-231 exhibited 
Stellate class which associates with a high 
degree of invasion capability. This finding 
consistent with molecular profile of this cell 
line for example Lin28 [23] and P53 mutation 
[24].MDA-MB-231 cell line also showed a 
predominant expression of follistatin, G-CSF, 
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HGF, leptin, and PDGF-BB by Bio-Plex 
analysis which are consistent with their 
implication in the progression and metastasis 
of prostate cancer because it showed 
significant expression of HGF and 
PDGF-BB[25]. In contrast, MDA-MB-231 
cells showed less expression of VEGFA and 
HIF-1 Alpha genes than AU-565 cells in the 
RT-PCR experiment, and this suggest that 
HER2 interact more closely with VEGFA and 
HIF-1 Alpha for stimulation of 
angiogenesis.Overall, the results indicated 
that MDA-MB-231 cell line is as aggressive 
as AU-565 cell line (which over-expresses 
HER2 receptors) and there are others factors 
other than HER2 contribute to the 
aggressiveness of angiogenesis in the tumors 
like P53 mutation, over-expression of EGF 
and TGF alpha.  
Conclusion  
Our data showed that the AU-565 cell line 
which over-expresses with the HER2 
receptors showed a significant decrease when 
the cells were treated with anti-HER2 
inhibitors in both tumor weight and 
hemoglobin measurement after they were 
implanted in nude mice in vivo. Also, it 
showed variable expression of angiogenesis 
factors and genes (mainly; VEGF, VEGFA, 
Angiopoietin, and IL-8) as compared with 
MCF-7 cell line which does not over-express 
HER2. This suggests that breast cancer with 
HER2/neuoncogenes is associated with more 
angiogenic activities which results in more 
aggressive behavior of this form of cancer. 
However, this data needs to be verified on a 
larger scale with more breast cancer cell lines 
in vivo and in vitro. Also, evaluation of 
angiogenesis by using histopathological 
methods and immuno-histochemnical markers 
on clinical samples will provide additional 
solid data to these findings. 
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